Skip to content

In the BioHarmony Drug Report Database

Azilsartan medoxomil

Edarbi (azilsartan medoxomil) is a small molecule pharmaceutical. Azilsartan medoxomil was first approved as Edarbi on 2011-02-25. It is used to treat hypertension in the USA. It has been approved in Europe to treat hypertension. Edarbi's patents are valid until 2028-03-26 (FDA).
Trade Name Edarbi
Common Name Azilsartan medoxomil
Indication hypertension
Drug Class Angiotensin II receptor antagonists
Azilsartan medoxomil
Get full access now